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Soft tissue sarcomas (STS) constitute a heterogeneous group of rare solid tumors associated with significant morbidity and
mortality. ,e evaluation and treatment of STS require a multidisciplinary team with extensive experience in the management of
these types of tumors. National and international clinical practice guidelines for STS do not always provide answers to a great
many situations that specialists have to contend with in their everyday practice. ,is consensus provides a series of specific
recommendations based on available scientific evidence and the experience of a group of experts to assist in decision-making by all
the specialists involved in the management of STS.
1. Introduction
Soft tissue sarcomas (STS) constitute a heterogeneous group
of rare solid tumors that account for only 1-2% of all cancers
in adults and 7% in children and adolescents [1]. ,e in-
cidence of STS, some 80 histological subtypes of which have
been identified to date [2], has risen over the past few years,
with an average annual increase of 1.8% between 2002 and
2012 [3]. ,e relative mortality for patients with extremity
and truncal STS at 5 and 10 years was determined to be
32.8% and 36.0%, respectively, and varied according to
patient age, grade of the disease, stage at diagnosis, and
comorbidities [4]. ,e selection of a treatment by a mul-
tidisciplinary team provides a basis for the management of
the STS and is absolutely essential to the improvement of
both the patient’s prognosis and quality of life [5, 6].
Nevertheless, despite the advances made in our knowledge
of the pathophysiology of the disease, the different national
[7, 8] and international [2, 9] clinical practice guidelines,
which have been developed using evidence collected from
the literature, do not provide answers to a great many sit-
uations that specialists have to contend with in their ev-
eryday practice. In this context, the consensus of a group of
experts can be a very useful tool. ,erefore, this Delphi
consensus on “Optimization of the therapeutic approach to
patients with Sarcoma” provides a series of specific rec-
ommendations based on available scientific evidence and the
experience of a group of experts to assist decision-making by
all the specialists involved in the management of STS.
2. Methodology
,e panel of experts of the Delphi consensus on “Opti-
mization of the therapeutic approach to patients with
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Sarcoma” was made up by 20 specialists from all across
Spain. ,ey were chosen for inclusion on the panel due to
their experience in the clinical management of patients
with STS.
,e Delphi method [10] was used to conduct the study
in order to optimize the consultation process among the 20
panel members. To this intent, for questions measured on a
metric scale, a level of agreement of more than 70% among
all the experts consulted on the “top 4” (score of 7 or more
points) was required to establish a consensus about each
one of the questions asked and, conversely, a level of
consensus equal to or greater than 70% was required for
the “bottom 4” (score of 3 or less points) to determine a
consensus about disagreement. On the other hand, for
questions measured on a nominal scale, where respon-
dents had to select one item or option from a nominal list
containing more than two items, a level of consensus equal
to or greater than 50%—“mode”—for the majority selected
option was required in order to establish an agreement
consensus. Lastly, for questions measured on an ordinal
scale, where respondents were asked to rank the various
items according to the degree of importance, a coefficient
of variation equal to or less than 40% was required for an
agreement consensus.
In total, there were 64 questions covering 7 different
categories or specialty areas, which were drafted by the co-
ordinators: localized high-risk disease, 10 questions (devel-
oped by J. M. B.); first-line treatment, 8 questions (developed
by A. L. P.); second-line and subsequent therapy, 8 questions
(developed by X. G. S.); metastasis surgery, 8 questions (de-
veloped by J. L. G.); retroperitoneal sarcomas, 10 questions
(developed by R. A. A.); gynecological sarcomas, 10 questions
(developed by J. C. J.); and disease follow-up, 10 questions
(developed by C. V. M.).
,e study methodology adopted a two-stage approach.
During the first stage, which took place from September 27
to November 13, 2017, and which aimed at defining the level
of consensus for the different issues that were raised, the 20
participating specialists (Appendix) responded anony-
mously to a totally structured online questionnaire that
contained metric (majority), nominal, and ordinal ques-
tions. ,e members of the Scientific Committee, who were
responsible for the systematic search of the literature for the
drafting of the questions, did not respond to the
questionnaire.
Questions that did not achieve a sufficient level of
consensus were submitted for inclusion in the second stage,
which took place online between December 19 and De-
cember 22, 2017, with the anonymous participation of 16 of
the 20 specialists included in the initial sample. Again, the
members of the Scientific Committee, who were responsible
for the analysis and identification of the issues where the
divergence of opinion was greatest, did not respond to the
questions included in the second stage.
Finally, after the coordinators had put the resulting
recommendations into writing, an in-person meeting was
held on January 25, 2018, in which the experts voted to
validate the recommendations.
3. Results and Discussion
3.1. Localized High-Risk STS. Localized high-risk (Table 1)
STS are defined as those that meet the following criteria: G3,
>5 cm, and deep-seated [11]. ,e panel of experts accepted
this definition and, in turn, determined that since not all
histological subtypes of G3 STS exhibit uniform behavior,
cases in which G2 is established by needle biopsy (Tru-Cut)
with necrosis of at least 50% seen on MRI should also be
considered high risk. On the other hand, the grading system
of the French Federation of Comprehensive Cancer Centers
(FCCCs) [12] should not be used in cases of myxoid lip-
osarcoma with transformation to a high-grade form with
cellularity greater than 5%—spindle cell or round cell.
,e results of the study by Tanaka et al. support the use
of preoperative chemotherapy followed by postoperative
chemotherapy consisting of three cycles of doxorubicin
60mg/m2 and ifosfamide 10 g/m2 for localized high-risk
extremity or trunk wall STS [13]. In this regard both, the
noninferiority of three cycles of a full-dose conventional
chemotherapy (epirubicin and ifosfamide) in comparison
with five cycles and the association between response to
therapy and better rates of overall survival (OS), particularly
when Choi criteria are used for the evaluation, have been
pinpointed in a randomized trial [11]. In light of the evi-
dence, the experts recommend perioperative chemotherapy
with anthracyclines and ifosfamide× 3 cycles for patients
with localized high-risk extremity or trunk wall STS, with
preference for neoadjuvant treatment because it seems to
improve survival and adds potential prognostic information.
While neoadjuvant chemotherapy is not widely accepted
in the approach to high-risk extremity and truncal STS,
numerous studies support the use of radiation therapy in this
situation, to the point where it is now considered a mainstay
of treatment for high-risk patients. Still, the addition of
chemotherapy to radiation therapy is associated with an
improvement in the local response rate, reduction of the
resection area, and a higher rate of preservation of the limb
affected by STS [11, 14]. Moreover, and at the very least,
potentially, chemotherapy can enhance the antitumor effects
of radiation therapy [14]. For this reason, in an effort to
improve the negative impact of potential R1 resection on
patients with localized high-risk extremity and truncal STS,
the panel of specialists recommends the use of preoperative
chemoradiation therapy in this situation. In this case, in the
event perioperative chemotherapy is used, the experts rec-
ommended the regimen of epirubicin 60mg/m2/day on days
1-2 + ifosfamide 3 g/m2/day on days 1–3 every 21 days.
When using this scheme, which can be delivered in an
outpatient setting, monitoring of nadir counts is recom-
mended at the very least in the first 2 cycles.,is regimen has
been evaluated in a joint study conducted by Sarcoma
Research Groups in Italy, Spain, and France against histo-
type-tailored chemotherapy, and no advantage has been
observed in the tailored regimen arm [15]. Additionally,
MESNA (40% of the total daily ifosfamide dose at 0, 3, and 6
hours after the start of ifosfamide) and G-CSF support
should be given in combination with this regimen.
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Alternatively, other equivalent regimens containing
anthracycline and ifosfamide are considered adequate in this
setting.
Likewise, the members of the panel agreed that patients
with soft tissue masses >5 cm that have experienced recent
growth or are deep-seated should be referred to a tertiary
care facility or one known for its expertise in sarcomas where
a needle biopsy (Tru-Cut) can be performed in order to
establish the diagnosis and allow the case to be discussed
with the multidisciplinary board.
After examining the evidence gathered from 33 articles,
Kandel et al.’s review [16] concluded that patients with
tumor-free margins have a better prognosis, so the authors
determined that the goal of the surgery for extremity STS
should be to achieve clear margins. Bearing this in mind,
there was a high level of consensus among the panel experts
when it came to recommending that surgical margins be
prioritized over limb function in patients with high-risk
extremity STS. If, in order to achieve adequate margins, limb
function cannot be preserved, then radical surgery should be
considered. Likewise, reoperation to widen margins should
be carried out on patients with extremity STS who have
positive margins after undergoing unplanned surgery.
Surgery is the treatment of choice for high-grade ret-
roperitoneal sarcoma [17]. Also, the study by Hager et al.
shows that adjuvant radiation therapy provides significant
benefits in the five-year survival rates in this situation [18].
In this regard, the experts agreed that surgery alone should
be recommended for the treatment of patients with high-
grade retroperitoneal sarcoma and that the procedure
should be carried out after proper planning at a tertiary care
facility or one renowned for its expertise in sarcoma.
Finally, the factors influencing the recommendation of
perioperative chemotherapy in patients with high-risk ex-
tremity or truncal STS are as follows: comorbidities, the
presence of which has a very negative impact on the patient’s
prognosis [19]; histological subtype, since chemosensitivity
varies very significantly according to the histology of the
tumor [20, 21]; and age, as the effectiveness of chemotherapy
with or without surgery and/or radiation therapy decreases
progressively with age [22]. On this point, the consensus
panel identified comorbidities, histological subtype, and age
as factors to be evaluated prior to the administration of
perioperative chemotherapy in high-risk STS and agreed it is
not recommended for the treatment of patients over the age
of 75.
3.2. First-Line Treatment. Anthracycline-based chemother-
apy is the mainstay of first-line treatment (Table 2) for
metastatic disease [2], specifically doxorubicin administered
intravenously at a dose of 60–75mg/m2 every 3weeks
[8, 23]. Likewise, the combination of doxorubicin and
ifosfamide may be the treatment of choice for STS subtypes
that are sensitive to ifosfamide and in those cases in which
the patient has good functional status [2]. Judson et al.
reported the results of a EuropeanOrganization for Research
and Treatment of Cancer (EORTC) randomized trial in first-
line treatment (doxorubicin vs. doxorubicin + ifosfamide)
and only recommend combination therapy when tumor
shrinkage is needed, at the cost of increased toxicity (Lancet
Oncology 2014, Judson) [24]. In this situation, in the phase II
clinical trial conducted by Tap et al. to assess doxorubicin
combined with olaratumab, a platelet-derived growth factor
Table 1: Treatment recommendations for localized high-risk soft tissue sarcomas.
Recommendation Phase Type of consensus (% agreement)
Tumor must be G3, >5 cm, and deep-seated for classification as high-risk extremity or
truncal STS 1 Yes (mode: 70%)
Treatment for high-risk extremity or truncal STS consists in the administration of the
following:
(i) 3 cycles of perioperative chemotherapy with full-dose epirubicin + ifosfamide 1 Yes (mode: 75%)
(ii) Preferably in the neoadjuvant setting 1 Yes (mode: 60%)
Use of preoperative (vs. postoperative) radiation therapy is recommended for high-risk
extremity or truncal STS, provided that the possibility of resection is marginal
(increased risk of R1)
1 Yes (mode: 70%)
,e recommended perioperative chemotherapy regimen for high-risk extremity or
truncal STS is as follows: epirubicin 60mg/m2/day as a 20min infusion on days 1-2 and
ifosfamide 3 g/m2/day as a 3-hour infusion on days 1–3 or equivalent regimens
1 Yes (mode: 100%)
Patients with a soft tissue mass >5 cm that have experienced recent growth or are deep-
seated should be referred to a tertiary care facility or one renowned for its expertise 1 Yes (mode: 90%)
Adequate surgical margins should be prioritized over limb function in patients with
high-risk extremity or truncal STS 1 Yes (mode: 90%)
If positive margins are confirmed, reoperation to widen surgical margins should always
be attempted in patients with high-risk extremity or truncal STS 1 Yes (mode: 85%)
Standard treatment for retroperitoneal sarcoma is surgery carried out after proper
planning at a tertiary care facility or one renowned for its expertise 1 Yes (mode: 50%)
Before administering perioperative chemotherapy to patients with high-risk extremity
or truncal STS, the following risk factors must be considered:
(i) Comorbidities 2 Yes (93.8)
(ii) Histological subtype 2 Yes (81.3)
(iii) Age 2 Yes (68.8)
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receptor alpha- (PDGFRα-) blocking antibody, the combi-
nation of olaratumab plus doxorubicin showed a significant
improvement in OS compared with doxorubicin alone, al-
though the response rate and progression-free survival were
slightly lower [25]. Nevertheless, the results of a phase III
trial (ANNOUNCE) presented at ASCO 2019 did not
confirm that olaratumab + doxorubicin, followed by olar-
atumab monotherapy, improves OS over doxorubicin alone
in patients with advanced STS.
,erefore, all of the panel experts agreed to recommend
doxorubicin 75mg/m2 administered as an intravenous in-
fusion every 3 weeks as first-line treatment for metastatic
disease. No consensus was reached for the combination of
doxorubicin and ifosfamide in this situation.
,e choice of first-line treatment for patients with ad-
vanced disease should be decided by a multidisciplinary
team with extensive experience in the management of STS
after taking patient age, functional status, comorbidities, and
the tumor location and histological subtype into consider-
ation [9]. Likewise, and in those cases where it is feasible,
complete resection of the metastases is the treatment of
choice, although the most definite experience has been with
the excision of lung lesions [7]. Hence, the consensus panel
determined that the most important factors to consider
when selecting the best first-line treatment for a patient
undergoing surgery for high-grade extremity STS with bi-
lateral pulmonary metastases are as follows: histological
subtype; comorbidities, age, and ECOG status of the patient;
the potential for surgical treatment of the metastases; and
progression-free survival greater than one year.
In the case of patients who underwent radical surgery for
primary tumor in advanced extremity STS, and who have
synchronous bilateral pulmonary metastases, the experts
recommend administering doxorubicin alone or in com-
bination with ifosfamide as first-line chemotherapy treat-
ment of choice, in addition to surgical resection of the
pulmonary metastases whenever possible. In this regard, the
panel did not reach a consensus on the appropriateness of
giving other types of chemotherapy (for example, doce-
taxel + gemcitabine), although there was a clear trend toward
consensus disagreement. On the other hand, with respect to
patients with resectable high-grade myxoid liposarcoma of
the thigh with M1 lung disease, the experts reached a
consensus with regard to starting standard chemotherapy
using doxorubicin + ifosfamide.
In conclusion, if feasible, surgical excision of the lung
metastases should be performed.
Some STS types could have a different sensitivity to
chemotherapy or are considered chemoresistants, for example,
alveolar soft part sarcoma (ASPS), a rare chemotherapy-re-
sistant STS that most commonly occurs in adolescents and
young adults; the consensus experts recommend that patients
should always be enrolled in clinical trials or given first-line
treatment with drugs that act against molecular targets, such as
VEGFR inhibitors, given the low response to chemotherapy in
this situation [26, 27]. Other chemoresistant histotypes were
not included in this panel discussion.
Finally, the experts reached a consensus in identifying
the administration of doxorubicin as the treatment of choice
for elderly female patients diagnosed with uterine leio-
myosarcoma with bilateral pulmonary metastases. In this
case, it is recommended to use doxorubicin monotherapy
and generally avoid local radiotherapy or chemotherapy in
combination.
Table 2: Recommendations for first-line treatment.
Recommendation Phase Type of consensus (% agreement)
,e first-line treatment of choice for metastatic disease is doxorubicin 75mg/m2
administered as an IV infusion every 3weeks 1 Yes (100)
,e most important factors to consider when selecting the best first-line treatment for
patients undergoing surgery for high-grade extremity STS with bilateral pulmonary
metastases are as follows:
(i) Histological subtype 1 Yes (90)
(ii) Comorbidities, age, and ECOG performance status of the patient 1 Yes (90)
(iii) Potential for surgical treatment of the metastases 1 Yes (90)
(iv) Duration of progression-free interval 1 Yes (80)
,e first-line treatment of choice for patients undergoing surgery for high-grade
extremity STS with bilateral pulmonary metastases is as follows:
(i) Doxorubicin alone 1 Yes (90)
(ii) Doxorubicin + ifosfamide 1 Yes (75)
(iii) Surgical resection of the pulmonary metastases 1 Yes (75)
,e treatment of choice for resectable high-grade myxoid liposarcoma of the thigh with
M1 lung disease is chemotherapy with doxorubicin + ifosfamide 2 Yes (68.8)
Standard chemotherapy regimens are not recommended for patients with metastatic
alveolar soft tissue sarcoma, given their limited activity; drugs that act against molecular
targets, such as VEGFR inhibitors, should be used instead
1 Yes (75)
Enrollment in a clinical trial should always be considered for these patients 1 Yes (85)
,e first-line treatment of choice for elderly female patients with metastatic uterine
leiomyosarcoma should be the following:
(i) Doxorubicin 2 Yes (68.7)
(ii) Doxorubicin + ifosfamide 2 No (87.5)
(iii) Local radiation therapy 2 No (68.8)
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3.3. Second-Line Treatment and Subsequent 9erapy.
Second-line treatment (Table 3) for advanced STS is always
palliative, so it should not be administered to asymptomatic
patients [8]. Although symptomatic patients should be
considered preferentially for inclusion in clinical trials,
different palliative options exist to control symptoms, such
as local radiation therapy, supportive medical treatment, and
supportive chemotherapy [8]. In this context, after pro-
gression to first-line chemotherapy, the members of the
panel recommend initiating treatment with the most active
therapy available for each case, as in subsequent lines efficacy
will decrease, and to prefer the less toxic alternatives as they
have a less negative impact on the quality of life. ,e experts
also determined that optimal treatment should include the
maximum possible number of drugs or regimens, to be used
sequentially following failure of a previous treatment,
provided the patient maintains adequate functional status.
,e selection of second-line treatment for STS should be
decided on an individual basis, taking into account both the
characteristics of the patient and the histological subtype of
the sarcoma, tumor burden, and expected toxicity [28, 29].
Along these lines, the consensus panel experts identified
comorbidity, age, and functional status of the patient as the
main factors to be assessed when choosing second-line
chemotherapy. Other aspects to consider, in decreasing
order of importance, are histological subtype, toxicity to
first-line chemotherapy, and the response to the first-line
chemotherapy.
Trabectedin has consistent activity in the different types
of STS, so that it can be considered for administration after
failure of first-line therapy with anthracyclines or in pa-
tients for whom anthracycline-based regimens are con-
traindicated [28]. Moreover, once the need for a change in
treatment has been confirmed, trabectedin has a relatively
favorable toxicity profile compared to other chemotherapy
agents [28]. Hence, the members of the consensus panel
agreed with the guidelines [2, 8] by considering that tra-
bectedin should always constitute an option when assessing
second-line treatment for the STS. On the other hand, in
addition to showing numerous data on its activity in
sarcoma subtypes other than leiomyosarcoma or lip-
osarcoma, particularly in the case of metastatic synovial
sarcoma [30], the studies have also confirmed the effec-
tiveness of trabectedin in modulating the transcription of
oncogenic fusion proteins, so it may be particularly useful
in the treatment of sarcomas derived from specific trans-
locations such as myxoid liposarcoma and Ewing sarcoma
[28]. ,e presence of t(12;16) or t(12;22) translocations
leads to FUS-CHOP or EWS-CHOP fusion proteins in
myxoid liposarcomas [31]. Consequently, in addition to
underline its use for the palliative treatment of synovial
sarcoma, the consensus experts agreed that treatment with
trabectedin is an especially valid option for myxoid lip-
osarcoma. Likewise, the panel also considers that the
reintroduction of trabectedin after progression in patients
who previously achieved a good response may be an option
to consider for selected patients. It is also recommended to
maintain treatment until disease progression in patients
with clinical benefit and acceptable tolerability.
Trabectedin discontinuation after the sixth treatment cycle
in patients with advanced soft tissue sarcoma who are free from
disease progression significantly shortens progression-free sur-
vival compared with patients who receive trabectedin contin-
uously. On the basis of these results, it is not recommended a
drug holiday in patients who benefit from trabectedin in terms
of tumor control after six courses of treatment [32].
,e response rate for ifosfamide as monotherapy for
second-line or subsequent treatment of STS varies between
4.8% and 62.5% across series [33], with an extremely poor
rate for leiomyosarcomas in particular [28]. Similarly, the
studies have shown that, in metastatic STS, the response rate
with ifosfamide is around 20–25% and mean OS is close to
12 months, which is comparable with outcomes for doxo-
rubicin [34]. Conversely, a retrospective analysis conducted
by the EORTC STS Group found that response rates were
higher for ifosfamide-based regimens versus doxorubicin-
based regimens in the second-line treatment of synovial
sarcomas [35]. In view of the above, and given the toxicity
and complex administration schedule of ifosfamide [28], the
panel recommended treatment with ifosfamide be consid-
ered only for certain subtypes and for those cases in which
the therapeutic objective is to achieve a rapid response, while
other more appropriate alternatives should be considered for
patients with leiomyosarcomas.
Pazopanib is the only oral agent approved for the
treatment of high-grade STS and can be considered an
acceptable option for different STS subtypes, excepting
liposarcomas, where the response rate is extremely poor
[29], after failure of first-line therapy with anthracyclines
[28]. Indeed, consensus experts agreed in calling attention to
its toxicity profile, which differs from that associated with
chemotherapy agents and may prove to be an advantage in
patients with significant toxicity to previous lines, although
it should never be considered for administration as second-
line therapy for liposarcoma and requires paying special
attention to the risks of hepatotoxicity, high blood pressure
(HBP), and hyperthyroidism. Unsurprisingly, the standard
oral dose of 800mg of pazopanib is associated with side
effects common to many anti-VEGF therapies, such as HBP,
thrombosis, proteinuria, hypothyroidism, cardiac dysfunc-
tion as well as gastrointestinal and hepatic disorders [36],
especially the elevations in transaminase levels [37]. ,e
PALETTE study, a randomized, double-blind, placebo-
controlled phase III study conducted by the EORTC STS
Group in patients withmetastatic STS, found an incidence of
7% of HBP in the control group and 41% in the pazopanib
arm [38]. On the other hand, the article by In et al. showed
that pazopanib has activity as second- and third-line
treatment for synovial sarcomas, undifferentiated pleo-
morphic sarcomas, and malignant peripheral nerve sheath
tumors and may even be considered for administration as
second-, third-, and even fourth-line therapy for select
patients with leiomyosarcoma [29]. In this regard, the
members of the panel considered that pazopanib constitutes
an adequate therapy option for third- or fourth-line treat-
ment of nonadipocytic STS.
On another note, the authors did not reach a consensus
when considering second-line treatment with eribulin as an
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effective therapy option for leiomyosarcoma. In that respect,
the improvement in OS with eribulin as compared with
dacarbazine was observed only in patients with liposarcoma
(OS 15.6 vs. 8.4 months, HR: 0.511, 95% CI: 0.3446–0.754),
but not in those with leiomyosarcoma (OS 12.7 vs. 13
months, HR: 0,927; 95% CI: 0.714–1.203) [39]. Moreover,
the benefit of treatment with eribulin for STS was limited to
overall survival, with no improvement found for progres-
sion-free survival [40]. However, the experts were unable to
reach a consensus when determining whether the fact of not
being associated with an increase in progression-free sur-
vival is a drawback for its use in the clinical setting.
Regarding combination therapy for second-line treat-
ment in advanced STS, there are a few data on clinical trials
comparing different schedules. ,e combination of gemci-
tabine and dacarbazine has activity in patients with previ-
ously treated STS [41–43], with a better tolerance profile
than the one observed with the combination of gemcitabine
and docetaxel in the SARC002 study [44]. To be specific, the
rate of progression-free survival (PFS) after three months of
treatment with the combination of gemcitabine and
dacarbazine was 46% in the study by Losa et al. [41] and 56%
in the one conducted by Garćıa del Muro et al. [42]. Ac-
cordingly, the experts noted that this combination, besides
Table 3: Recommendations for second-line and subsequent therapy.
Recommendation Phase Type of consensus (% agreement)
Optimal treatment following progression to first-line chemotherapy should
(i) Include the maximum possible number of drugs or regimens, to be used
sequentially following failure of a previous treatment, provided the patient maintains
an adequate performance status
1 Yes (85)
(ii) Be initiated with the most active therapy available for each case, taking into
account both histotype and specific patient characteristics, as in subsequent lines
efficacy will decrease
1 Yes (90)
(iii) Given the palliative context, give priority to less toxic alternatives as they have a
less negative impact on the quality of life 1 Yes (80)
,e following factors should be considered when selecting second-line treatment (in
decreasing order of importance):
(i) Comorbidity, age, and performance status of the patient 2 Yes (mean: 3.8; CV: 11.9%)
(ii) ,e sarcoma histological subtype 2 Yes (mean: 3.6; CV: 25.2%)
(iii) Toxicity to first-line chemotherapy 2 Yes (mean: 1.6; CV: 38.1%)
(iv) Response to first-line chemotherapy 2 Yes (mean: 1.6; CV: 40.3%)
(1) Trabectedin has a favorable toxicity profile compared to classic chemotherapy
agents and constitutes a second-line option that is always worth considering when
treating STS
1 Yes (90)
(2) Numerous data on activity in sarcoma subtypes other than leiomyosarcoma or
liposarcoma, such as synovial sarcoma, support the possibility of also using trabectedin
to treat these STS subtypes
1 Yes (75)
(3) Treatment with trabectedin is an especially recommended option for myxoid
liposarcoma 1 Yes (100)
(4) Treatment with trabectedin until progression may extend time to progression and is
an option worth considering for patients as it shows clinical benefit and acceptable
tolerance
1 Yes (95)
(5) Rechallenge with trabectedin after progression in patients who previously achieved
a good response may be an option to consider for select patients 1 Yes (75)
(6) Given its toxicity and complex administration schedule, ifosfamide is preferably
indicated for certain subtypes and for cases in which the therapeutic objective is to
achieve a rapid response
2 Yes (68.8)
(7) Other more appropriate alternatives than ifosfamide should be considered for
second-line treatment of leiomyosarcoma 2 Yes (93.8)
(8) Due to its toxicity profile, which is different from that of chemotherapy agents,
pazopanib may prove to be an advantage in patients with significant toxicity to previous
lines
1 Yes (90)
(9) Pazopanib should never be used for the treatment of liposarcomas 2 Yes (87.5)
(10) Pazopanib constitutes an adequate option for second-line and subsequent
treatment of nonadipocytic STS 2 Yes (68.8)
(11) Blood pressure and hepatic and thyroid function should be monitored during
treatment with pazopanib 2 Yes (93.8)
(12) Overall, the combination of gemcitabine and DTIC has a better tolerance profile
than gemcitabine plus docetaxel 1 Yes (95)
(13) ,e combination of gemcitabine and DTIC may be a treatment alternative to be
considered for leiomyosarcoma as well as the rest of STS 1 Yes (90)
(14) Given its lower activity compared to other available drugs, DTIC should no longer
be used for standard control arm patients in randomized second-line clinical trials 1 Yes (70)
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having a better tolerance profile, in general than the com-
bination of gemcitabine and docetaxel, may constitute a
treatment alternative to be considered not only for leio-
myosarcoma, but also for the rest of STS. In this regard, the
phase II clinical trial conducted by Garćıa del Muro et al.,
which compared gemcitabine plus dacarbazine versus
dacarbazine alone, found higher and statistically significant
OS rates (16.8 months vs. 8.2 months) and progression-free
survival rates for the combination therapy [42]. As a result,
and taking its lower activity in comparison with other
available alternatives into account, the panel’s members
concluded that dacarbazine should no longer be used for
control arm patients in randomized second-line clinical trials.
3.4. Metastasis Surgery. Although the existing international
consensus is that patients with STS should be referred to a
specialist sarcoma center for treatment, in our country 50% of
STS larger than 5 cm are operated on without a previous
diagnosis of sarcoma being established [8]. In this regard, all of
the members of the panel agreed with clinical practice
guidelines [5, 45] requiring that patients with advanced STS be
managed at centers with a sarcoma specialist multidisciplinary
team—including radiologists, pathologists, medical and ra-
diation oncologists, surgeons, and psychologists—with expe-
rience in the management of these types of tumors. ,e
experts also reached a consensus on the need to propose
surgical removal of the primary tumor to all patients with good
functional status who are diagnosed with resectable STS and
have multiple asymptomatic pulmonary metastases (Table 4).
,e objective of any treatment should be to improve the
quality of life for the patient. In this sense, palliative surgery
can provide significant relief of symptoms, especially of pain,
in properly selected patients with metastatic STS [46]. For this
reason, the members of the consensus panel considered
palliative surgery to be a good option for the treatment of
patients with advanced STS who are progressing on systemic
treatment andwho have symptomaticmetastases, regardless of
their location, recommending palliative surgery for metastases
as prophylaxis for symptoms or complications—among
others, fractures, gastrointestinal compressions, and hemor-
rhages—as long as it can be effective for their palliation.
Although to date no phase III clinical trials have been
conducted to compare surgery to the other therapy options
in local treatment of metastatic STS, numerous retrospective
studies suggest that radical tumor resection provides in-
creased survival in this situation [47]. Radiation therapy and
thermal radiofrequency ablation, as shown by Stragliotto et
al. and Lindsay et al., represent valid alternatives for the
treatment of metastasis when surgery is not indicated or
feasible.
In light of this evidence, experts identified SBRT and
surgery as the most reliable local treatment options for
oligometastatic disease, although no consensus was reached
with regard to thermal ablation.
Patients with metastatic STS generally have an ex-
tremely poor prognosis despite whatever treatment they are
receiving. Patients with isolated lymph node metastases
should be considered as potentially curable and should
undergo radical surgery for both the primary tumor and the
metastases.,is approach would be not applicable for those
patients with pulmonary metastases, in which the treat-
ment objective is less clear since the probability of cure is
much more remote. ,erefore, in case of pulmonary me-
tastases, the possibility of including the patient in a clinical
trial or initiating chemotherapy with palliative intent
should be evaluated [46]. In view of the above, the members
of the consensus panel recommended including all patients
with bilateral pulmonary metastases from STS in whom
complete resection cannot be achieved in clinical trials.
Finally, a meta-analysis by Treasure et al. found a 5-year
survival rate of 25% after a first pulmonary metastasectomy
for patients with STS, with better survival found in cases
where there were fewer metastases and longer intervals
between diagnosis of STS and the appearance of metastases
[50]. ,at notwithstanding, the authors underscore that
there is no evidence to support that metastasectomy will
lead to an increase in survival for STS patients, suggesting
that the higher survival observed for patients undergoing
surgery vs. those who had no surgery can be explained by
the fact that the patients selected for this type of procedure
are usually those who have a better prognosis, rather than
due to the effect of metastasectomy in itself. Keeping this in
mind, the panel’s experts recommended considering pul-
monary metastasectomy only for cases in which the pul-
monary metastases, whether unilateral or bilateral, are
resectable, and always taking into account patient func-
tional status and the progression-free interval.
3.5. Retroperitoneal Sarcoma. ,e guidelines by the Grupo
Español de Investigación en Sarcomas (GEIS) (Spanish Sar-
coma Research Group) [8] make it mandatory to perform a
core needle biopsy for all retroperitoneal sarcomas (Table 5) if
neoadjuvant therapy is planned, other abdominal tumors are
evaluated for differential diagnosis, or there is reasonable
clinical suspicion of sarcoma in the presence of a retroperi-
toneal lesion. In addition, and as occurs for most STS, fine-
needle aspiration (FNA) cytology is not suitable for a primary
diagnosis of retroperitoneal sarcomas. In the same line, the
guidelines published in 2018 by ESMO and the European
Reference Network for Adult Rare Solid Cancers (EUR-
ACAN) [2] acknowledge the need for biopsy prior to starting
any treatment in order to establish a pathological diagnosis of
retroperitoneal sarcoma and thus facilitate making both
present and future treatment decisions. ,e standard pro-
cedure consists in using a coaxial needle with an appropriate
gauge (14–16G) to obtain a multiple core biopsy, a procedure
associated with minimal risk of dissemination in the needle
tract. Accordingly, the panel of experts recommended per-
forming core needle biopsy for retroperitoneal sarcomas
whenever neoadjuvant radiation and/or chemotherapy is
planned and determined that the risk of dissemination in the
needle tract, which is minimal, should not be a reason for not
performing this procedure and that under no circumstances
should FNA be performed instead, as the latter provides little
diagnostic information and can only cause delays in starting
potential therapy.
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Because of their complexity, retroperitoneal sarcomas
should always be treated in centers that have multidisci-
plinary teams with experience in the management of these
types of tumors [51]. Surgery is the mainstay of treatment for
primary lesions and the only curative option for retroper-
itoneal sarcoma, and it must be performed by a surgeon with
specific experience in this type of STS [2]. Indeed, the
surgical team must be prepared, or have the necessary help,
to perform techniques such as bowel resection, nephrec-
tomies, or diaphragm reconstruction [8]. For these reasons,
the members of the panel determined that patients with
retroperitoneal sarcoma must always be referred to a tertiary
care facility or one known to have a multidisciplinary team/
committee with extensive surgical experience in the man-
agement of tumors at this location.
In this context, after a patient has been referred for
assessment following inadequate primary surgery—no en-
bloc resection, R0, and so on—of retroperitoneal sarcoma at
a hospital center lacking experience, the treatment approach
will depend on the grade of the disease. Hence, in cases of
low-grade retroperitoneal sarcoma, the authors recommend
performing a CT scan of the thorax, abdomen, and pelvis
(CT TAP scan) and set up a schedule to follow up closely in
the absence of clear disease data until development of the
macroscopic lesions, at which time a new surgery should be
planned. On the other hand, in cases of high-grade disease,
treatment should be tailored according to patient charac-
teristics. Likewise, with regard to the treatment of local
recurrence of retroperitoneal sarcoma, rescue surgery
should only be considered for cases in which the disease is
resectable and R0 can be achieved.
,e level of evidence is not enough to support the
routine use of radiation therapy complementary to surgery.
Although retrospective studies suggested that adding ra-
diotherapy to treatment could reduce the risk of local re-
currence, there are no randomized studies confirming it.,e
randomized, phase III STRASS (EORTC-STBSG 62092–
22092) failed to demonstrate the benefit of preoperative
radiotherapy in the treatment of localized retroperitoneal
sarcomas. However, in the exploratory analysis, a possible
benefit of this treatment was described in the LPS subgroup
[52]. ,e experts on this consensus panel agreed to the
determination that when a decision is made to use com-
plementary radiation therapy for patients who have po-
tentially resectable retroperitoneal sarcoma, preoperative
radiation therapy should always be administered as long as it
is possible to meet with the radiation field requirements.
Although to date no randomized clinical trials to
compare neoadjuvant therapy with radical surgery alone for
retroperitoneal sarcoma have been conducted, neoadjuvant
treatments such as chemotherapy or external beam radiation
therapy (EBRT) are safe for select patients, so their use can
be assessed subject to a review by the multidisciplinary team
[2]. ,e GEIS guidelines establish that even though, gen-
erally speaking, neoadjuvant chemotherapy is not recom-
mended, it may be indicated in specific cases when there are
realistic expectations of improving resectability [8]. On this
point, the panel members agreed that neoadjuvant che-
motherapy should be considered for high-grade retroperi-
toneal sarcomas with potential sensitivity to chemotherapy
(leiomyosarcoma, angiosarcoma, synovial sarcoma, etc.)
that are at the limits of resectability.
Table 4: Recommendations for metastasis surgery.
Recommendation Phase Type of consensus (% agreement)
Patients with advanced sarcoma should be managed at centers with a
multidisciplinary team (radiologists, pathologists, surgeons/traumatologists,
medical and radiation oncologists, psychologists, and physiotherapists)
specializing in sarcoma treatment
1 Yes (100)
Primary tumor surgery should always be considered for patients with ECOG
≤2 who have resectable soft tissue sarcoma and multiple asymptomatic
pulmonary metastases
1 Yes (mode: 50%)
Palliative surgery for metastases may be an option for patients with advanced
sarcoma who are progressing on systemic treatment and who have
symptomatic metastases
2 Yes (68.8)
,e most reliable local treatment options for oligometastatic disease are as
follows:
(i) Surgery 1 Yes (80)
(ii) Stereotactic body radiation therapy (SBRT) 2 Yes (87.5)
For the purpose of preventing symptoms or complications, palliative surgery
for metastases from sarcoma should always be performed as long as it will be
effective for palliation
2 Yes (mode: 85%)
Inclusion in a clinical trial should be considered for all patients with
pulmonary metastases from STS when palliative treatment may be an option
and it proves impossible to achieve an R0 resection
1 Yes (95)
Pulmonary metastasectomy should only be considered when the pulmonary
metastases, whether unilateral or bilateral, are resectable, and always taking
into account the following factors:
1 Yes (mode: 75%)
(i) ECOG 2 Yes (mode: 50%)
(ii) Progression-free interval 2 Yes (mode: 50%)
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Given the absence of evidence to show increase in survival,
adjuvant chemotherapy should not be administered on a
routine basis for surgically resected retroperitoneal sarcomas.
,e study by Datta et al. [53] compared OS associated with
surgery alone vs. adjuvant chemotherapy in 767 patients with
retroperitoneal sarcomas who had been surgically resected.
,e results showed that the use of adjuvant chemotherapy was
associated with decreased long-term survival (median OS: 47.8
vs. 68.9 months, p � 0.017; HR: 1.30, 95% CI: 1.05–1.61).
Hence, the experts determined that since adjuvant chemo-
therapy cannot be considered standard treatment for resected
retroperitoneal sarcomas, in the event that it is considered as
an option in some individual cases, the factors that should be
assessed are, in decreasing order of importance, risk of relapse,
histology, and histological grade. Furthermore, should such a
treatment choice be made, a regimen consisting of anthra-
cycline-ifosfamide would be administered.
3.6. Gynecological Sarcomas. When surgical resection is not
feasible, the treatment for advanced recurrent endometrial
stromal sarcoma (ESS) is administration of systemic hormone
therapy with palliative intent [54]. According to the estab-
lished definition, ESS is a low-grade sarcoma characterized by
a high expression of estrogen (ER, 40–100%) and proges-
terone (PgR; 60–100%) receptors [55], which is why hormone
treatments to reduce estrogen levels play a central role in the
management of ESS and are more effective than the different
chemotherapy regimens [56]. In this regard, given their ef-
ficacy and tolerability, both the aromatase inhibitor letrozole
as well as progestins could be the treatment of choice for
patients with recurrent or residual unresectable ESS [57].
Conversely, in cases in which the disease has become resistant
to estrogen deprivation, chemotherapy should be indicated,
although with less favorable outcomes [55]. On the basis of
this evidence, the experts determined that, for the treatment
with palliative intent of unresectable ESS that expresses es-
trogen receptors, the first therapy option should be hormone
treatment using aromatase inhibitors rather than anthracy-
cline-based chemotherapy (Table 6).
,e mainstay of treatment for localized ESS is radical
abdominal hysterectomy with bilateral salpingo-
Table 5: Recommendations for retroperitoneal sarcomas.
Recommendation Phase Type of consensus (% agreement)
Performance of core needle biopsy for the diagnosis of retroperitoneal sarcoma (RS)
(i) Must always be carried out if neoadjuvant therapy is planned (radiation therapy
and/or chemotherapy) 1 Yes (95)
(ii) It must not be replaced by FNA, as it provides little diagnostic information and
can cause delays in starting potential treatment 1 Yes (90)
(iii) Has minimal risk of dissemination in the needle tract, so this should not be a reason
for not performing this procedure 1 Yes (75)
Patients with RS should always be referred to a tertiary care facility or one renowned for
its expertise and known to have a multidisciplinary team/committee with extensive
surgical experience in the management of tumors at this location
1 Yes (mode: 85)
,e procedure to be followed in patients who are referred for assessment after
inadequate RS surgery (no en-bloc resection, R0, etc.) performed at a hospital center
lacking the necessary experience depends on the grade:
(i) Low-grade RS: performance of CT TAP scan and follow up closely in the absence
of clear disease data until development of macroscopic lesions, at which time a new
surgery should be performed
1 Yes (mode: 50%)
(ii) High-grade RS: treatment should be tailored to each case, as there are no clear
recommendations in this regard 1 Yes (mode: 50%)
Rescue surgery should be considered as treatment for local RS recurrence in cases in
which the disease is resectable and R0 can be achieved 1 Yes (mode: 80%)
Complementary radiation therapy cannot be used as standard treatment for patients
who have potentially resectable RS; if after individualized assessment it is indicated,
preoperative radiation therapy will be administered in every case as long as it is possible
to meet the radiation field requirements
2 Yes (93.8)
Neoadjuvant chemotherapy should be considered for high-grade RS with potential
sensitivity to chemotherapy (leiomyosarcoma, angiosarcoma, synovial sarcoma, etc.)
that are at the limits of resectability
1 Yes (75)
Given the absence of evidence to show increase in survival, adjuvant chemotherapy
cannot be considered standard treatment for resected RS; hence, if considered as an
option in individual cases, the factors that should be assessed are (in decreasing order of
importance) as follows:
(i) Risk of relapse 2 Yes (mean: 4.0; CV: 28.9%)
(ii) Histology 2 Yes (mean: 3.9; CV: 22.8%)
(iii) Histological grade 2 Yes (mean: 3.3; CV: 32.5%)
In the event that the decision is made to treat resected RS with adjuvant chemotherapy,
the regimen to be administered would consist of a combination of an anthracycline and
ifosfamide
1 Yes (mode: 50%)
Sarcoma 9
oophorectomy [56]. Given the elevated expression of ER and
PgR receptors, hormone replacement therapy after surgery is
contraindicated [58], as is adjuvant radiation therapy, whose
use in this situation has been shown to be ineffective [59].
Very few studies have been conducted to evaluate the ef-
fectiveness of chemotherapy in this situation. ,e work by
Kim et al. found that adjuvant chemotherapy had no effect on
the prognosis of patients with stage I low-grade ESS [60].
Likewise, the multivariate analysis by Feng et al. showed that
use of multiple chemotherapy regimens may improve pro-
gression-free survival in low-grade localized ESS, although the
results were inconclusive [61]. Similarly, a lack of clinical trials
means that, at present, we cannot determine whether hor-
mone therapy can be beneficial in the general approach to all
low-grade ESS or whether it should only be administered to
patients at high risk for recurrence [61]. In view of the sit-
uation, the US National Comprehensive Cancer Network
(NCCN) recommends close observation without treatment
after surgery for stage I ESS [62]. On their side, the consensus
panel experts determined that the administration of hormone
therapy with letrozole should not be recommended after
radical surgery for localized low-grade ESS expressing es-
trogen receptor.
Early and complete resection constitutes the best
treatment option for uterine leiomyosarcoma confined to
the neck and body of the uterus [63, 64]. ,e largest case
series study performed to date shows that the ability to
achieve complete tumor cytoreduction is associated with a
statistically significant increase in disease-free survival [65].
Under these circumstances, the current clinical practice is to
perform hysterectomy with bilateral oophorectomy. How-
ever, the incidence of occult ovarian (<4%) and lymph node
(<3%) metastases in uterine leiomyosarcoma is very low and
they are usually associated with extrauterine disease [66]. In
this respect, the study by Kapp et al. failed to show a sig-
nificant difference in 5-year disease-specific survival between
patients who underwent or did not undergo bilateral oo-
phorectomy at the time of hysterectomy [67]. In conse-
quence, the panel of experts recommended performance of
simple hysterectomy as the surgical treatment of choice for
uterine leiomyosarcoma and stated that bilateral oopho-
rectomy is not necessary. On the other hand, in case of
advanced, unresectable uterine leiomyosarcoma, the deci-
sion to initiate palliative systemic treatment will be deter-
mined by the grade of disease.
,e clinical practice guidelines published by the British
Sarcoma Group determine that any patient with a sus-
pected STS should be referred to a diagnostic center for
assessment by a specialist sarcoma multidisciplinary team
expert in the management of these types of tumors [45].
Likewise, the joint guidelines published by the European
Sarcoma Network Working Group (ESNWG) and the
European Society for Medical Oncology (ESMO) clearly
state that a multidisciplinary approach is mandatory for all
patients with STS and must involve pathologists, radiolo-
gists, surgeons, radiation therapists, and oncologists,
among other specialists, and that management should be
carried out at a tertiary care facility or a center known for its
expertise in sarcomas and having a multidisciplinary team/
committee and treating a high number of patients every
year [5]. ,us, the consensus panel recommended that all
gynecological sarcomas be referred to an interdisciplinary
team for assessment, to thus reach agreement on what type
of treatment would be best for the individual patient,
determining the need to set up some form of consultation
during the decision-making process before the gynecolo-
gists, who are usually responsible for the diagnosis of these
tumors, make the surgical decision.
3.7. Disease Follow-Up. After the treatment of the primary
STS, 11–14% of patients develop local recurrences and
between 18% and 50% end up developing metastases
[45, 68]. ,e 2018 guidelines published by the US National
Comprehensive Cancer Network (NCCN) [9] recommends
local follow-up of patients with high-grade STS every 3–6
months during the first 2–3 years, every 6 months until the
fifth year, and annually from the sixth year onwards. For
patients with low-grade STS, local follow-up is recom-
mended every 3–6 months during the first 2–5 years and
annually from the sixth year onwards. For its part, the
ESMO-EURACAN guidelines [2] recommend that surgi-
cally treated patients with intermediate-high-grade STS be
followed every 3-4 months during the first 2-3 years, every 6
months until the fifth year, and annually from the sixth year
onwards. However, both the NCCN and the ESMO and the
EURACAN acknowledge that there is a lack of evidence in
the literature regarding the effectiveness of these recom-
mendations, indicating the need for prospective clinical
trials to be conducted in this regard (Table 7).
Table 6: Recommendations for gynecological sarcomas.
Recommendation Phase Type of consensus (% agreement)
First-line palliative treatment for unresectable stromal sarcoma should be hormone
treatment with letrozole 1 Yes (70)
After surgery for localized stromal sarcoma, hormone treatment with letrozole should
be administered 2 No (75)
Simple hysterectomy is the surgical treatment of choice for uterine leiomyosarcoma 2 Yes (93.8)
,e histological grade of the uterine leiomyosarcomas determines the type of palliative
systemic treatment 2 Yes (75)
When a gynecological sarcoma is diagnosed, the case must be referred to an
interdisciplinary team for agreement on what type of treatment would be best for the
individual patient
2 Yes (75)
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A study by Sawamura et al. [69] retrospectively reviewed
the records of 867 patients with STS who were treated
surgically, with the aim of evaluating the time elapsed be-
tween resection of the tumor and the diagnosis of local
recurrences, the time elapsed between surgery and the di-
agnosis of distant metastases, and the difference in those
parameters based on tumor size and grade. Low-grade STS
consistently recurred during follow-up and developed me-
tastasis very rarely, so the authors recommended follow-
up—physical examination andMRI—every 6months during
the first 5 years and annually from the sixth year until the
tenth year. On the other hand, high-grade STS had a higher
rate of local recurrence and metastases than low-grade STS,
especially during the first two years, leading the authors to
recommend follow-up—physical examination and MRI-
—every 3 months during the first two years, then every 6
months up to the fifth year, and annually from the sixth year
until the tenth year. Regardless of the grade, 95% of local
recurrences and metastases were detected during the first 9
years of follow-up, so the authors do not see any justification
for continuing the follow-up after the tenth year.
,e recommendations of the panel of experts regarding
the follow-up of the disease are included in Table 6.
,ere is a paucity of evidence in the literature re-
garding the effectiveness of different follow-up strategies,
including the use of MRI or CT scans. Indeed, to date, no
studies have been published to show that the use of CT
scans during routine follow-up of patients with STS can be
associated with an improvement in prognosis [9]. ,e
ESMO-EURACAN guidelines note that although the use
of MRI to detect local recurrences and CT scans for
pulmonary metastases may allow these episodes to be
Table 7: Recommendations for disease follow-up.
Recommendation Phase Type of consensus (% agreement)
Patients with excised low-grade STS who had negative resection margins should have
(i) Local MRI every 6 months during the first 2 years, as well as a physical exam every
3 or 6 months if considered appropriate 2 Yes (mode: 50)
(ii) Physical exam every 6 months and local MRI annually from 3rd to 5th year 2 Yes (mode: 68.3)
(iii) Physical exam and local MRI annually from 6th to 10th year 2 Yes (mode: 68.3)
(iv) No follow-up is necessary after 10th year 1 Yes (mode: 65)
Patients with low-grade resected STS with focally positive margins that cannot be
widened should have the following:
(i) Physical exam and local MRI every 3-4 months during the first 2 years 1 Yes (mode: 70)
(ii) Physical exam and local MRI every 6 months from 3rd to 5th year 1 Yes (mode: 65)
(iii) Physical exam and local MRI annually from 6th to 10th year 1 Yes (mode: 70)
(iv) No imaging tests are necessary after 10th year, and no further follow-up can be
considered vs. annual physical exam 2 —
Patients with high-risk (>5 cm, deep-seated, and high-grade) resected STS with focally
positive margins that cannot be widened and who have only received complementary
radiation therapy should have the following:
(i) Physical exam and local MRI every 3-4 months during the first 2 years 1 Yes (mode: 80)
(ii) Physical exam and local MRI every 6 months from 3rd to 5th year 1 Yes (mode: 80)
(iii) Physical exam and local MRI annually from 6th to 10th year 1 Yes (mode: 85)
(iv) No imaging tests are necessary after 10th year, and no further follow-up can be
considered vs. annual physical exam 2 —
Patients with (<5 cm, deep-seated, and high-grade) resected STS with focally positive
margins that cannot be widened and who have only received complementary radiation
therapy should have the following:
(i) Physical exam and local MRI every 3-4 months during the first 2 years 1 Yes (mode: 80)
(ii) Physical exam and local MRI every 6 months from 3rd to 5th year 1 Yes (mode: 75)
(iii) Physical exam and local MRI annually from 6th to 10th year 1 Yes (mode: 75)
(iv) No imaging tests are necessary after 10th year, and no further follow-up can be
considered 2 Yes (mode: 56)
Patients with localized intermediate-high-grade STS should have a chest CTscan every
3-4 months during the first 2 years, every 6 months from 3rd to 5th year, and thereafter
annually until 10th year
1 Yes (mode: 70)
After resection of the pulmonary metastases, patients who have had metastatic disease
should have a lung CT scan every 3 months during the first 2 years and subsequently
every 6 months
1 Yes (80)
Factors to be taken into account to consider that a patient has progressed on a
treatment and needs to change to a different one are as follows(in decreasing order of
importance):
(i) Clinical progression 2 Yes (mean: 3.3; CV: 23.9%)
(ii) Progression based on RECIST criteria 2 Yes (mean: 3.1; CV: 25.2%)
PET-CT scans are considered especially useful prior to the resection of pulmonary
metastases from STS 2 Yes (75)
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found earlier, it has not been shown that this is beneficial
or cost-effective, compared with the clinical assessment of
the primary tumor and regular chest X-rays [2]. Keeping
this in mind, the members of the panel recommend
performing CT scans every 12 weeks in the follow-up of
patients with metastatic disease receiving active treatment
or no treatment, but whose general condition is good and
lung CT scans every 3 months during the first two years
and every 6 months after the third year after resection of
the pulmonary metastases.
Likewise, consensus experts identified the appearance or
worsening of symptoms as the primary factor for consid-
ering that a patient has progressed on a treatment and needs
to change to a different one, followed by progression based
on RECIST criteria.
Finally, several studies have confirmed the usefulness of
PET-CT scans to predict the course of the disease and
monitor response to therapy [70, 71], although their use has
to be seen as standard for the majority of patients. ,e
ESMO-EURACAN guidelines note that it is mandatory to
perform an abdominal CT scan and a bone scan or an 18F-
FDG PET-CT scan in order to confirm that the lung me-
tastases are “isolated” [2]. In this regard, the expert con-
sensus identified PET-CT scans as an especially useful tool
prior to the resection of pulmonary metastases from STS.
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